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The challenges of integrating new genetic tests into health-
care, using the example of hereditary breast cancer, were
recently raised by Resta (2009) in his Commentary
“Unprepared, Understaffed and Unplanned: Thoughts on
the Practical Implications of Discovering New Breast and
Ovarian Cancer Causing Genes” and in Commentary
responses by Hampel (2009) and Uhlmann (2009). I
appreciate the thoughtful points that Dr. Edward Taubman
makes in his Letter to the Editor (2010) about these
Commentaries. While I agree with Dr. Taubman that
genetic testing companies and insurers are key players, I
respectfully disagree about the roles he proposes for each of
them in informing patients about genetic testing advances.
Dr. Taubman accurately notes that insurers’ policies limit
who can be covered for testing but I disagree that they have
a responsibility “to help inform their clients when some-
thing more informative comes along.” It is impractical for
insurance companies to keep on top of genetic testing
advances and inform patients, especially given the large
number of genetic conditions and the fact that laboratories
may offer different tests for the same condition. There are
over 6,800 genetic conditions (Online Mendelian Inheri-
tance in Man [OMIM]) and currently there are over 1,600
genetic tests with a couple hundred more in the research
pipeline (GeneTests). Testing decisions can be complex
because depending on the genetic condition, laboratories
can differ in genes and mutations tested, methodologies,
test sensitivities and costs; therefore, determining whether
genetic testing is indicated, which test should be ordered
and appropriate laboratory selection are critical. Determin-
ing whether genetic testing is now more informative for a
patient will require genetics/specialists’ expertise, especial-
ly since few genetic tests currently have practice guidelines
and/or are considered standard of care. Insurance compa-
nies have a limited number of physicians to review
coverage requests for testing and genetics background of
most physicians is also limited.
What is practical is to work with insurance companies
for better coverage of genetic testing. As noted in the
Secretary’s Advisory Committee on Genetics, Health and
Society 2006 report on Coverage and Reimbursement of
Genetic Tests and Services, problems with coverage and
reimbursement of genetic tests and services are limiting
their accessibility and integration into the health care
system. I propose that genetic tests should be ordered by
primary care physicians if consistent with practice guide-
lines and/or considered standard of care and other genetic
tests should be ordered by geneticists/specialists, given the
expertise needed to make genetic testing determinations,
select the laboratory and interpret test results. To increase
efficiency in making insurance coverage decisions about
genetic testing, I propose the following:
■ If genetic testing is ordered consistent with practice
guidelines and/or is considered standard of care for a
condition, it should be covered.
■ If a geneticist or other specialist is requesting a
genetic test, it should be covered. Sure, some tests may
be inappropriately ordered but in general, paperwork
and time to review testing requests and insurance
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claims could be cut significantly if it was presumed
that the specialist physician ordering the test used their
expertise to make this determination. The geneticist/
specialist in making the decision to offer the patient a
genetic test should give careful consideration as to how
good is the test/how likely is it that a mutation(s) will
be identified, whether test results would impact their
patient’s medical care, life decisions and/or have
implications for other atrisk family members.
■ When a patient with a genetic condition has at-risk
family members, cover the genetic test. For many
genetic conditions, gene mutation(s) need to be
identified in an affected family member first before
at-risk family members can be tested. While other at-
risk family members may not be insured by the same
insurer, insurers’ agreement to cover genetic testing on
these affected individuals would globally enable at-risk
individuals in their and other insurance plans to be
tested. For a number of genetic conditions, ruling out
familial gene mutation(s) in at-risk family members
can save healthcare dollars by eliminating the need for
costly tests and evaluations that would otherwise
regularly be needed for surveillance. For at-risk family
members who have positive genetic test results, timely
surveillance/medical care can be initiated, which can
potentially reduce complications and also globally
lower healthcare costs.
■ Additional genetic testing by different methodologies
and retesting in the future may be indicated and this
should be covered if a geneticist/specialist makes the
testing request.
■ Cover DNA banking so cost is not a barrier for patients.
It is also impractical for genetic testing laboratories to have
the responsibility of helping to notify patients though Dr.
Taubman makes the excellent point that they have databases
with patients’ test results and could easily identify who needs
retesting. Some laboratories do send clinicians announce-
ments about test changes and new genetic tests and may even
send updated reports of results when testing advances change
the interpretation of previous test results. While commercial
laboratories may havemore resources to inform patients about
testing advances, many genetic tests are performed in
academic laboratories that generally lack resources to mount
media campaigns and recontact patients. There are other
logistical challenges in recontacting patients discussed in the
Commentaries by Resta (2009), Hampel (2009) and
Uhlmann (2009) including time required, patients relocating
and for insurers and genetic testing laboratories, the fact that
some may cease to exist. Globally in medicine, we do not
expect testing laboratories and insurers to notify patients
about the availability of more informative testing—why
should this be different for genetic testing?
What genetic testing laboratories can do is 1) include
information on their website on test parameters (e.g.
sensitivity) to make it easy to ascertain when advances
have been made for genetic tests that they offer 2) note in
reports if other genetic testing methodologies and/or
retesting in the future should be considered 3) note that a
clinical genetics evaluation may be indicated (a genetic test
does not take the place of a genetics evaluation and other
conditions and genetic tests may be diagnostic consider-
ations) 4) include in their test reports that DNA banking
should be considered when no mutation(s) are identified in
an affected individual, particularly if the condition is life-
limiting, to preserve the option for future testing. If a
genetic testing laboratory does not offer DNA banking,
consideration should be given to contracting with a
laboratory that does in order to make this service readily
available to their patients. As Dr. Taubman notes, unfamil-
iarity with DNA banking is “limiting how often it is done.”
Dr. Taubman proposes just having a box on genetic
testing forms that patients simply could check to have their
DNA banked when having genetic testing done. However,
consenting patients for DNA banking is quite different than
consenting patients for a genetic test. For DNA banking,
one must specify to whom the sample can be released for
future genetic testing. Family dynamics may complicate
who the family member is willing to release the sample to
and family members who may need access to the sample in
the future may be denied access or may not yet be born. In
addition, there will be potential ethical issues including a
family member accessing a banked DNA sample when
other at-risk relatives in the family line have decided not to
learn their carrier status; testing could potentially reveal the
carrier/future affected status of family members who have
decided not to learn this information. Relatives’ knowledge
that DNA has been banked on a family member and where
it has been banked are an issue. A DNA bank in each state
or a national centralized DNA bank could solve the issue
but this would then raise more issues that would need to be
resolved including use, privacy and access. It is important
to globally address DNA banking issues including length of
storage; family members, clinicians and researchers sample
access; and release of samples for future testing and to
educate patients, physicians and other allied healthcare
providers on the availability of DNA banking.
Patients’ personal medical and family histories are not
static and neither are genetic testing and other aspects of
medical care. The onus needs to be on patients to seek regular
healthcare and inquire whether advances have been made in
testing that will benefit their care (Uhlmann 2009). Determin-
ing when a test is ready to be a test (particularly a challenge
for rare genetic conditions) and communicating genetic
testing advances to patients and healthcare providers will
take collaboration with the genetics community, laboratories,
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groups involved in genetic testing oversight, insurers, disease
advocacy groups and other key stakeholders.
Incorporating advances in genetic testing and genomic
medicine in healthcare will take a multi-pronged approach and
involve many stakeholders. As Dr. Taubman notes, genetic
testing companies and insurers are two key teammembers that
need to be involved. The time to engage in discussion is now
and we need to work on hearing from diverse stakeholders,
figuring out how to best inform patients and healthcare
providers about advances so that genetic testing and genomic
medicine are successfully integrated into healthcare.
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